These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30965138)
21. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Soussain C; Choquet S; Fourme E; Delgadillo D; Bouabdallah K; Ghesquières H; Damaj G; Dupriez B; Vargaftig J; Gonzalez A; Houillier C; Taillandier L; Hoang-Xuan K; Leblond V Haematologica; 2012 Nov; 97(11):1751-6. PubMed ID: 22581000 [TBL] [Abstract][Full Text] [Related]
22. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642 [TBL] [Abstract][Full Text] [Related]
23. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G; Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815 [TBL] [Abstract][Full Text] [Related]
24. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R; Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936 [TBL] [Abstract][Full Text] [Related]
25. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Houillier C; Taillandier L; Dureau S; Lamy T; Laadhari M; Chinot O; Moluçon-Chabrot C; Soubeyran P; Gressin R; Choquet S; Damaj G; Thyss A; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Tanguy ML; Al Jijakli A; Morel P; Bourquard P; Moles MP; Chauchet A; Gastinne T; Constans JM; Langer A; Martin A; Moisson P; Lacomblez L; Martin-Duverneuil N; Delgadillo D; Turbiez I; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C; J Clin Oncol; 2019 Apr; 37(10):823-833. PubMed ID: 30785830 [TBL] [Abstract][Full Text] [Related]
26. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743 [TBL] [Abstract][Full Text] [Related]
27. Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. Delphine L; Pierre-Edouard D; Bruno R; Bérengère G; Magalie J; Patrick V; Jean-Pierre M; Pierre M Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36810481 [TBL] [Abstract][Full Text] [Related]
28. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593 [TBL] [Abstract][Full Text] [Related]
29. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings? de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167 [TBL] [Abstract][Full Text] [Related]
31. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394 [TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Illerhaus G; Kasenda B; Ihorst G; Egerer G; Lamprecht M; Keller U; Wolf HH; Hirt C; Stilgenbauer S; Binder M; Hau P; Edinger M; Frickhofen N; Bentz M; Möhle R; Röth A; Pfreundschuh M; von Baumgarten L; Deckert M; Hader C; Fricker H; Valk E; Schorb E; Fritsch K; Finke J Lancet Haematol; 2016 Aug; 3(8):e388-97. PubMed ID: 27476790 [TBL] [Abstract][Full Text] [Related]
34. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026 [TBL] [Abstract][Full Text] [Related]
35. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401 [TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466 [TBL] [Abstract][Full Text] [Related]
37. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. Puckrin R; Chua N; Shafey M; Stewart DA Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424 [TBL] [Abstract][Full Text] [Related]
38. [Autologous peripheral blood stem cell transplantation for treating primary central nervous system lymphoma: a single-center retrospective study]. Okubo Y; Kaneko H; Shimizu T; Nomura R; Hyuga M; Mitsuyoshi T; Tada K; Ukyo N; Mizutani C; Hatanaka K; Imada K Rinsho Ketsueki; 2018; 59(1):33-39. PubMed ID: 29415935 [TBL] [Abstract][Full Text] [Related]
39. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma. Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207 [TBL] [Abstract][Full Text] [Related]
40. Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Scordo M; Morjaria SM; Littmann ER; Bhatia A; Chung HH; Maloy M; DeAngelis LM; Giralt SA; Taur Y; Sauter CS Biol Blood Marrow Transplant; 2018 Sep; 24(9):1914-1919. PubMed ID: 29679773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]